Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2401 4th Ave Ste 1050 SEATTLE WA 98121-3460 |
Tel: | N/A |
Website: | aptevotherapeutics.com |
IR: | See website |
Key People | ||
Marvin L. White President, Chief Executive Officer, Director | Daphne L. Taylor Chief Financial Officer, Senior Vice President | Jeffrey G. Lamothe Chief Operating Officer, Executive Vice President | So Young Kwon Senior Vice President, General Counsel, Business Development and Corporate Affairs |
Business Overview |
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family. |
Financial Overview |
For the fiscal year ended 31 December 2023, Aptevo Therapeutics Inc revenues decreased from $3.1M to $0K. Net loss before extraordinary items totaled $18.7M vs. income of $7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Gain on extinguishment of liability rela decrease from $37.2M (income) to $0K. |
Employees: | 40 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$28.31M as of Dec 31, 2023 |
Net annual income (TTM): | -$18.65M as of Dec 31, 2023 |
Free cash flow (TTM): | -$11.73M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 3,594,058 as of Apr 17, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |